热门资讯> 正文

Belite Bio报告第二季度业绩

2026-08-13 22:44

Belite Bio press release (BLTE): Q2 non-GAAP net loss of $21.6M, compared to a non-GAAP net loss of $8.7M for the same period in 2025.
Cash and Cash Equivalents: As of June 30, 2026, the company had $279.9M in cash and cash equivalents, compared with $352.9M on December 31, 2025.

More on Belite Bio

Belite Bio: The Oral Route Is The Real Competitive Moat
Belite Bio, Inc (BLTE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Belite Bio, Inc (BLTE) Presents at 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) - Slideshow
Belite Bio wins FDA priority review for lead candidate
These 10 mid-cap U.S. healthcare companies carry the market's most expensive valuations

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。